Cyclerion Therapeutics (CYCN) Competitors $3.64 +0.09 (+2.54%) Closing price 07/11/2025 03:50 PM EasternExtended Trading$3.59 -0.05 (-1.37%) As of 07/11/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. KPTI, EGRX, ACRV, PEPG, AKTX, XCUR, BRNS, MRSN, ARTV, and ELYMShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Karyopharm Therapeutics (KPTI), Eagle Pharmaceuticals (EGRX), Acrivon Therapeutics (ACRV), PepGen (PEPG), Akari Therapeutics (AKTX), Exicure (XCUR), Barinthus Biotherapeutics (BRNS), Mersana Therapeutics (MRSN), Artiva Biotherapeutics (ARTV), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Karyopharm Therapeutics Eagle Pharmaceuticals Acrivon Therapeutics PepGen Akari Therapeutics Exicure Barinthus Biotherapeutics Mersana Therapeutics Artiva Biotherapeutics Eliem Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts prefer KPTI or CYCN? Karyopharm Therapeutics presently has a consensus target price of $37.40, indicating a potential upside of 721.98%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is KPTI or CYCN more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Karyopharm Therapeutics' return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-43.99% N/A -35.95% Cyclerion Therapeutics N/A -34.02%-30.68% Which has more volatility & risk, KPTI or CYCN? Karyopharm Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Which has higher valuation & earnings, KPTI or CYCN? Cyclerion Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.27-$76.42M-$13.26-0.34Cyclerion Therapeutics$2M5.84-$3.06M-$1.16-3.14 Does the media refer more to KPTI or CYCN? In the previous week, Karyopharm Therapeutics had 4 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.25 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Karyopharm Therapeutics Neutral Cyclerion Therapeutics Very Positive Do institutionals and insiders have more ownership in KPTI or CYCN? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 3.0% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCyclerion Therapeutics beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.40M$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-3.1420.5827.9620.25Price / Sales5.84292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book1.117.638.045.49Net Income-$3.06M-$55.05M$3.18B$250.27M7 Day Performance10.14%8.39%3.63%4.75%1 Month Performance17.42%5.35%4.04%7.64%1 Year Performance8.66%1.95%29.55%16.34% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.0083 of 5 stars$3.64+2.5%N/A+7.7%$11.40M$2M-3.1430Positive NewsGap DownKPTIKaryopharm Therapeutics3.9367 of 5 stars$4.31-1.8%$43.20+902.3%-68.5%$37.93M$145.24M-0.32380News CoverageAnalyst ForecastGap DownEGRXEagle Pharmaceuticals2.4524 of 5 stars$2.90+7.4%N/A-41.1%$37.66M$257.55M0.00100News CoverageGap DownACRVAcrivon Therapeutics3.9657 of 5 stars$1.19-0.8%$17.71+1,388.6%-83.3%$37.63MN/A-0.5458Positive NewsPEPGPepGen3.1007 of 5 stars$1.11-3.5%$7.67+590.7%-92.7%$37.63MN/A-0.3530AKTXAkari Therapeutics0.8644 of 5 stars$1.17+0.9%N/A-68.0%$37.30MN/A0.009XCURExicure1.4915 of 5 stars$7.04+19.5%N/A+2,115.8%$37.21M$500K-1.8450Positive NewsGap DownHigh Trading VolumeBRNSBarinthus Biotherapeutics3.4493 of 5 stars$0.93+1.5%$6.25+572.0%-30.3%$36.95M$14.97M-0.57107Positive NewsMRSNMersana Therapeutics4.0367 of 5 stars$0.30+1.7%$5.20+1,656.8%-83.1%$36.27M$40.50M-0.50150Gap UpARTVArtiva Biotherapeutics3.0212 of 5 stars$1.51+2.7%$17.80+1,078.8%N/A$35.81M$250K0.0081Positive NewsELYMEliem TherapeuticsN/A$1.18-6.3%N/A-80.9%$35.11MN/A-2.239High Trading Volume Related Companies and Tools Related Companies KPTI Competitors EGRX Competitors ACRV Competitors PEPG Competitors AKTX Competitors XCUR Competitors BRNS Competitors MRSN Competitors ARTV Competitors ELYM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
